Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Pseudomonas aeruginosa versus gemcitabine for prevention of postoperative recurrence in non-muscle-invasive bladder cancer
ChiCTR1900026643Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Nov 2019
- Modality
- Small Molecules, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of gemcitabine and pseudomonas aeruginosa injection, sponsored by Second Hospital of Lanzhou University. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
gemcitabinepseudomonas aeruginosa injection
Beyond the preview
Go deeper on ChiCTR1900026643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026643.